Screener
MoonLake Immunotherapeutics MLTX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from MoonLake Immunotherapeutics’s reported figures.
Based on the most recent quarter.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026. Open the filing →
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
FAQ
- What is MoonLake Immunotherapeutics's debt-to-equity?
- MoonLake Immunotherapeutics (MLTX) reported debt-to-equity of 0.4× in Q1 2026.
- How has MoonLake Immunotherapeutics's debt-to-equity changed year-over-year?
- MoonLake Immunotherapeutics's debt-to-equity increased by 113.9% year-over-year, from 0.2× to 0.4×.
- What is the long-term trend for MoonLake Immunotherapeutics's debt-to-equity?
- Over 3 years (2022 to 2025), MoonLake Immunotherapeutics's debt-to-equity has grown at a 250.0% compound annual growth rate (CAGR), from 0× to 0.2×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about MoonLake Immunotherapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude